Arbutus Biopharma (ABUS) Misses Q3 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat